---

$16.66

-0.9190 ( -5.23% ) 180.7K

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-07-31	Sale	-1785.00	Mohideen Pharis
2024-05-29	Sale	-382.00	Mohideen Pharis
2024-03-11	Buy	17094.00	Tasse Daniel
2024-02-08	Buy	1825.00	Ndu Adora
2023-12-19	Sale	-2245.00	Mohideen Pharis
2023-11-22	Sale	-35000.00	Mohideen Pharis
2023-11-22	Sale	-19000.00	Boucinha Virginie
2023-11-22	Sale	-806672.00	Tasse Daniel
2023-08-28	Buy	12000.00	MORRIS TIMOTHY E
2023-08-14	Sale	-764386.00	Tasse Daniel